Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LNA043 in Symptomatic Knee Osteoarthritis
NCT04864392Phase 2Terminated
- Sponsor
- Novartis
- Start
- May 2021
- Primary completion
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 15
01
Overview
A Phase 2 trial of LNA043 in osteoarthritis (OA), sponsored by Novartis. Started May 2021; status: terminated.
02
Drugs
LNA043
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT04864392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04864392.